Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
305 articles
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Clinical trial results for oral icotrokinra in treating plaque psoriasis across adult and adolescent patients published in NEJM.
New research reveals atopic dermatitis has multiple biological subtypes, each requiring personalized treatment approaches.
New research identifies Lp-PLA2 enzyme as therapeutic target for deadly lung disease affecting millions of workers worldwide.
Scientists develop potent α5β1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
New spatial multiomics study maps cellular interactions in systemic sclerosis, revealing fibroblast-macrophage dynamics.
New research reveals how IL-35 therapy prevents neutrophil trap formation, offering hope for cigarette smoke-worsened asthma.
Review examines immunosuppressive drugs like cyclosporine and tacrolimus, highlighting new applications and safety management strategies.
New research reveals how IGF2BP3 protein promotes inflammation and tissue damage in rheumatoid arthritis through RNA modifications.
Expert commentary on pemphigus foliaceus, a rare autoimmune blistering disease affecting skin health and immune function.
Delphi study of 166 Italian neurologists establishes guidelines for individualized MS therapy based on patient needs and drug characteristics.
